EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase II)Open Access

Efficacy and Safety of Ammoxetine in Major Depressive Disorder

Shen He, Jing-Xu Chen, XueQin Yu, Huali Lin, ZhiQiang Wang, Xuan Li, Yanan Zhou, Yan-Song Liu, Hongyan Zhang, Jicai Wang, Cuixia An, Hao Liu und 3 weitere

JAMA Network Open · 2025

DOI: 10.1001/jamanetworkopen.2025.32650 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, 2025. Verfasst von Shen He und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Major Depressive Disorder, Morpholines, Serotonin and Noradrenaline Reuptake Inhibitors. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Major depressive disorder (MDD) is among the most prevalent mental health disorders, causing substantial disability and economic burden. Although several first-line treatments exist with mild adverse effects, up to 50% to 60% of patients do not tolerate or respond to them. Ammoxetine, a novel selective serotonin and norepinephrine reuptake inhibitor, has been found to reduce adverse effects and hepatotoxicity and more potent inhibition of serotonin and norepinephrine transporters, making it more tolerable and effective.

Objective

To evaluate the efficacy and safety of ammoxetine in treating adults with MDD. Design, Setting, and Participants This phase 2 randomized clinical trial was a multicenter, double-masked, placebo-controlled, parallel-group, fixed-dose study of ammoxetine treatment in patients with MDD in China. Patients aged 18 to 65 years from 15 study centers were randomized into daily ammoxetine or placebo groups between March 27, 2023, and June 13, 2024, and followed up for 10 weeks.

Interventions

Participants were randomized 1:1:1 to 3 treatment groups: ammoxetine 40 mg/d, ammoxetine 60 mg/d, and placebo. Main Outcome and Measures The primary outcome was change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score from baseline to 8 weeks. Efficacy analyses were performed on both the full-analysis and per-protocol sets using least-squares (LS) mean differences. The safety set analysis was performed using descriptive statistics.

Results

Among 239 enrolled patients (mean [SD] age, 30.4 [10.0] years, 158 female [66.1%]), 80 were randomized to the ammoxetine 60 mg/d group, 80 to the ammoxetine 40 mg/d group, and 79 to the placebo group. In the full-analysis set, both ammoxetine doses led to statistically significant improvements in MADRS total scores at week 8 compared with placebo. The LS mean changes (SE) from baseline were −16.7 (1.3) for ammoxetine 40 mg/d, −16.6 (1.3) for ammoxetine 60 mg/d, and −13.5 (1.3) for placebo. The differences vs placebo were −3.3 (97.3 CI, −6.3 to −0.3) for ammoxetine 40 mg/d and −3.1 (97.3% CI, −6.2 to 0.0) for ammoxetine 60 mg/d. Consistent results were observed in the per-protocol set analysis at week 8 for ammoxetine 40 mg/d (LS mean change, −3.2; 97.3% CI, −6.2 to −0.2) and ammoxetine 60 mg/d (LS mean change, −3.18; 97.3% CI, −6.2 to −0.2), both superior to placebo. Treatment-emergent adverse events were reported in 68 participants (85.0%) receiving ammoxetine 60 mg/d, 63 (78.8%) receiving ammoxetine 40 mg/d, and 48 (60.8%) receiving placebo; most were mild to moderate in severity. Conclusions and Relevance This randomized clinical trial demonstrated superiority over placebo of ammoxetine treatment at both 40 mg/d and 60 mg/d in patients with MDD. In addition, all doses of ammoxetine were generally well tolerated. Trial Registration ClinicalTrials.gov Identifier: NCT05762458

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Major Depressive DisorderMorpholinesSerotonin and Noradrenaline Reuptake InhibitorsAdolescentAdultAgedFemaleHumansMaleMiddle AgedYoung AdultChinaDouble-Blind MethodTreatment OutcomePropylaminesBenzodioxoles

Substanzen

MorpholinesammoxetineSerotonin and Noradrenaline Reuptake InhibitorsPropylaminesBenzodioxoles

Autor:innen und Institutionen

  • Department of Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Sleep Medicine Center, Beijing Huilongguan Hospital, Beijing, China.
  • Chongqing Mental Health Center, Chongqing, China.
  • Xi'an Mental Health Center, Xi'an, China.
  • Wuxi Mental Health Center, Wuxi, Jiangsu, China.
  • Guangzhou Medical University Affiliated Brain Hospital, Guangzhou, Guangdong, China.

Zitieren

APA

He, S., Chen, J. X., Yu, X., Lin, H., Wang, Z., Li, X., Zhou, Y., Liu, Y. S., Zhang, H., Wang, J., An, C., Liu, H., Li, C., Ni, S., & Li, H. (2025). Efficacy and Safety of Ammoxetine in Major Depressive Disorder. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2025.32650

Vancouver

He S, Chen JX, Yu X, Lin H, Wang Z, Li X, et al. Efficacy and Safety of Ammoxetine in Major Depressive Disorder. JAMA Network Open. 2025. doi:10.1001/jamanetworkopen.2025.32650

BibTeX
@article{He2025,
  author = {He, Shen and Chen, Jing-Xu and Yu, XueQin and Lin, Huali and Wang, ZhiQiang and Li, Xuan and Zhou, Yanan and Liu, Yan-Song and Zhang, Hongyan and Wang, Jicai and An, Cuixia and Liu, Hao and Li, Chao and Ni, Shaonan and Li, Huafang},
  title = {Efficacy and Safety of Ammoxetine in Major Depressive Disorder},
  journal = {JAMA Network Open},
  year = {2025},
  doi = {10.1001/jamanetworkopen.2025.32650}
}
Kostenlos starten →